Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 August 2013Website:
http://www.precigen.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 92 min agoDividend
Analysts recommendations
Institutional Ownership
PGEN Latest News
GERMANTOWN, Md. , May 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a webcast on June 3, 2024 at 6:00 PM CT/7:00 PM ET following the late-breaking oral presentation of results from the pivotal study of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Precigen, Inc. (PGEN) reported a quarterly loss of $0.10 per share, slightly missing the Zacks Consensus Estimate of a loss of $0.09. This is the same as the loss of $0.10 per share reported in the same quarter last year.
FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis is expected in the 2nd half of 2024. It is projected that it could earn $2 billion in peak sales globally of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis.
Precigen, Inc. (PGEN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PGEN's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Precigen, Inc. (NASDAQ:PGEN ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Jason Butler - JMP Securities Jennifer Kim - Cantor Fitzgerald Arthur He - H.C. Wainwright Ben Burnett - Stifel Brian Cheng - JPMorgan Operator Good morning and welcome to the Precigen Second Quarter and First Half 2023 Financial Results and Business Update Call.
What type of business is Precigen?
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
What sector is Precigen in?
Precigen is in the Healthcare sector
What industry is Precigen in?
Precigen is in the Biotechnology industry
What country is Precigen from?
Precigen is headquartered in United States
When did Precigen go public?
Precigen initial public offering (IPO) was on 08 August 2013
What is Precigen website?
https://www.precigen.com
Is Precigen in the S&P 500?
No, Precigen is not included in the S&P 500 index
Is Precigen in the NASDAQ 100?
No, Precigen is not included in the NASDAQ 100 index
Is Precigen in the Dow Jones?
No, Precigen is not included in the Dow Jones index
When does Precigen report earnings?
The next expected earnings date for Precigen is 09 August 2024